OРИГИНАЛЬНЫЕ СТАТЬИ

Ganchimeg Ulziisaikhan¹, Mungun-Ulzii Khurelbaatar¹, Chingerel Khorloo², Naranchimeg Sodovsuren², Altaiasaikhan Khasag², Tsolmon Unurjargal²
¹ National cardiovascular center of Mongolia, the Third state central hospital, Ulaanbaatar, Mongolia
² Mongolian national university of medical sciences, Ulaanbaatar, Mongolia

ASSESSMENT OF GLOBAL LONGITUDINAL STRAIN AND PLASMA NATRIURETIC PEPTIDE IN PATIENTS WITH ASYMPTOMATIC LEFT VENTRICULAR DYSFUNCTION

Objective
The purpose of this study was to investigate the association between global longitudinal strain (GLS) and plasma NT-proBNP for predicting left ventricular (LV) performance in asymptomatic patients after acute myocardial infarction (AMI).

Material and methods
We prospectively included patients with diagnosis of AMI without clinical signs and symptoms of heart failure (HF) and followed these patients for 6 mos. Baseline echocardiography was performed at admission, and follow-up echocardiography was performed after 6 mos. A normal GLS was defined as having an absolute value of ≥16%. According to the baseline GLS, participants were divided into two groups and compared. In all participants, blood samples of plasma NT-proBNP were obtained at admission, before discharge, and 6 mo after discharge.

Results
The study population was consisted of 98 participants, of which 80 (81.6%) were males, and the mean age was 56.0±9.3 years. Baseline echocardiography showed that most of the participants (60, 61.2%) had abnormal GLS<16%, whereas 38 (38.8%) participants had normal or borderline GLS ≥16%. Compared with the normal GLS group, participants with abnormal GLS had higher GRACE score, higher troponin I concentration, lower systolic blood pressure, lower mean LV ejection fraction, and decreased LV diastolic function. At 6-mo follow-up, only LV systolic function remained significantly different between the two groups. Compared to baseline, there was a significant improvement of GLS in the abnormal GLS group at 6-mo follow-up (p=0.04). Prevalence of complications after AMI was significantly higher in this group. There were significant differences between baseline and discharge NT-proBNP concentrations between the two groups (p<0.05). In the abnormal GLS group, there were significant correlations between baseline and discharge NT-proBNP concentrations with baseline LV systolic function. Discharge NT-proBNP concentration also correlated significantly with 6-mo follow-up GLS. For determining the effect of baseline GLS abnormality, the areas under the ROC curve for baseline and discharge NT-proBNP concentrations were 0.73 (95% CI 0.60–0.85, p=0.001) and 0.77 (95% CI 0.66–0.87, p<0.001), respectively. Regarding early prediction of follow-up GLS abnormality, the area under the ROC curve for discharge NT-proBNP concentration was significantly higher 0.70 (95% CI 0.55–0.84, p=0.016). The optimum cut-off value of discharge NT-pro-BNP was 688.5 pg / ml, with 72.4% sensitivity and 65.4% specificity to predict 6-mon GLS abnormality following acute myocardial infarction.

Conclusion
The main finding of this study is that impaired LV GLS is associated with elevated plasma concentrations of NT-proBNP in post-AMI patients. Pre-discharge NT-proBNP concentration combined with impaired initial GLS could predict worsening LV systolic function over time in asymptomatic post-AMI patients.

Keywords
Myocardial infarction; natriuretic peptide; echocardiography; left ventricular dysfunction

For citation
Ganchimeg Ulziisaikhan, Mungun-Ulzii Khurelbaatar, Chingerel Khorloo, Naranchimeg Sodovsuren, Altaiasaikhan Khasag, Tsolmon Unurjargal. Assessment of global longitudinal strain and plasma natriuretic peptide in patients with asymptomatic left ventricular dysfunction. Kardiologiia. 2021;61(10):53–60. [Russian: Ганчимег Улзийсайхан, Мунгун-Улзий Хурелбаатар, Чингерел Хорлоо, Наранчимег Содовсурэн, Алтайсайхан Хасаг, Цолмон Унуржаргал. Оценка общей продольной деформации и плазменного уровня натрийуретического пептида у пациентов с бессимптомной дисфункцией левого желудочка. Кардиология. 2021;61(10):53–60]

Corresponding author
Ganchimeg Ulziisaikhan. E-mail: ganchimeg@telemedicine.mn

Introduction
In Mongolia, the incidence of cardiovascular disease, which is the first leading cause of mortality and the third leading cause of morbidity, has doubled over the last 20 yrs [1]. Among cardiovascular diseases, ischemic heart disease is the most prevalent [2]. Left ventricular (LV) systolic dysfunction is a frequent and severe complication of ischemic heart disease. It is particularly associated with myocardial infarction (MI), which increases the risk of sudden death and heart failure (HF) [3]. Asymptomatic LV systolic dysfunction (ALVSD)
is defined as depressed LV systolic function in the absence of signs and symptoms of clinical heart failure [4]. SAVE and TRACE trial results show that 40–58% of post-MI patients developed ALVSD. Post-infarction ALVSD is also associated with a higher risk of adverse events, including progressive HF and mortality [5, 6]. Thus, early recognition of ALVSD in such patients could reduce adverse clinical outcome.

Currently, in patients with acute MI (AMI), routine echocardiography is advised, and LV ejection fraction (LVEF) is a key parameter for assessing LV systolic function. In fact, recent studies have shown that imaging of global longitudinal strain (GLS) is more sensitive to ischemia and wall tension, and is able to detect irregular contraction patterns even with normal LVEF [7, 8]. Longitudinally directed, subendocardial fibers of LV myocardium are more susceptible to ischemia. Thus, subendocardial dysfunction in early ischemia would be expected to affect longitudinal directed fibers and result in further reduction in longitudinal strain [9]. Furthermore, data suggest that GLS is able to diagnose subclinical LV dysfunction [10] and to predict the prognosis of post-MI mortality independently of LVEF [11].

Natriuretic peptides (NPs) are secreted by cardiomyocytes as a result of pressure or volume overload. Although several forms of NPs have been identified, N-Terminal pro-B-type natriuretic peptide (NT-proBNP) is routinely used for diagnosis of HF, and it plays an important role in predicting outcomes and in monitoring therapeutic effectiveness. The mechanism of increasing NT-proBNP in post-MI patients with asymptomatic LV dysfunction remains unclear. Myocardial ischemia is a powerful stimulus, and, independently of changes in LVEF, it was demonstrated to induce release of NT-proBNP [12]. Previous studies described that a high concentration of NT-proBNP is associated with poor prognosis after acute coronary syndrome [13]. Recently, there has been increased interest in using plasma NT-proBNP to distinguish clinically asymptomatic patients at risk of future cardiac events.

Several studies have examined relationships between GLS and NPs, but they have mainly assessed chronic HF and cardiotoxicity. However, the link between myocardial global longitudinal deformation and neuro-hormonal activation in patients with asymptomatic LV dysfunction after AMI is poorly understood. Therefore, the aim of this study was to investigate the association between GLS and plasma NT-proBNP for predicting LV performance in asymptomatic patients post AMI.

**Material and methods**

**Study design and patient population**

We prospectively included 100 patients with diagnosis of AMI without HF. Clinical signs and symptoms and followed for 6 mos. Two participants were excluded due to incidence of acute HF during hospitalization. Thus, the study analysis was based on 98 patients. All the patients were admitted to the Coronary Care Unit of the National Cardiovascular Center at The Third State Central Hospital of Mongolia. AMI was diagnosed if a patient had acute myocardial ischemia related symptoms, dynamic electrocardiographic changes, i.e., ST-segment changes or newly discovered pathological Q wave, increased cardiac troponin, and imaging evidence of newly discovered loss of viable myocardium or regional wall motion abnormalities associated with ischemic etiology [14]. Exclusion criteria were patients with previous diagnosis and clinical symptoms of HF, age >75 years, confirmed atrial fibrillation, valvular heart disease, congenital heart disease, cardiomyopathy, kidney dysfunction, pulmonary hypertension, chronic obstructive pulmonary disease, liver cirrhosis, or anemia, since these conditions are associated with increased NT-proBNP [15].

The study was approved by the Ethics Committee of the Mongolian National University of Medical Sciences and by the Biomedical Ethics Committee of Ministry of Health of Mongolia. All participants provided written informed consent.

Demographic variables, signs and symptoms, initial hemodynamic findings (heart rate and blood pressure), cardiac risk factors, co-morbidities, past medical history and the findings of initial investigations such as blood test results, ECG data were collected from inpatient records. HF related signs and symptoms were re-obtained prior to discharge. All participants underwent immediate primary percutaneous coronary intervention (PCI). Findings in relation to coronary angiography, including the culprit lesion, number of diseased vessels, and post PCI final TIMI (Thrombolysis In Myocardial Infarction) flow grade were also obtained. Medical treatment data were collected before discharge and during follow-up visits.

**NT-proBNP assay**

Blood samples for NT-proBNP were obtained from all participants at admission. These samples are designated as “baseline samples.” Samples obtained before discharge and within 3–5 days after admission are designated as “discharge samples”, and samples obtained 6 mos after discharge are designated as “6-mo samples”. Blood samples were collected into tubes containing EDTA. The blood samples were stored at 4°C and centrifuged within 24 hrs. The resulting plasma was immediately frozen and stored at -80°C. NT-proBNP was measured with an immunoassay analyzer (FIA8000, Getein Bio Medical Inc, China).

**Echocardiography**

Echocardiographic images were obtained with a Philips iE33 Ultrasound system. Baseline echocardiography was...
performed at admission, and follow-up echocardiography was performed after 6 mos. The biplane Simpson's method was used for assessing LVEF. Two-dimensional speckle tracking measurements of GLS were performed in the two, three, and four chamber apical views. At end systole, the endocardial border was automatically traced and identified as a region of interest (ROI). The investigator visually assessed the detected ROI and, if necessary, manually adjusted the ROI to ensure that the speckles were tracked correctly. If the tracking covered the entire cardiac wall from the endocardium, it was considered adequate. A normal GLS was considered to be an absolute value of ≥16% [16]. All echocardiographic analysis were performed by a single, experienced operator.

### Table 1. Baseline clinical characteristics for the AMI participants stratified according to GLS

| Characteristic                      | All patients (n=98) | Patients according to baseline GLS | p value |
|------------------------------------|---------------------|-----------------------------------|---------|
|                                    |                     | Less than 16% (n=60) | Greater than 16% (n=38) |         |
| Age, yrs                           | 56.0±9.3            | 56.4±8.8             | 55.0±10.0          | 0.405   |
| Sex, men                           | 80 (81.6%)          | 47 (78.3%)           | 33 (86.8%)         | 0.289   |
| BMI, kg/m²                         | 27.7±4.53           | 27.2±4.50            | 28.5±4.52          | 0.177   |
| GRACE score                        | 101.9±17.14         | 106.4±16.27          | 95.2±16.40         | 0.003*  |
| Time from onset to hospital admission |                     |                     |                     |         |
| Less than 12 hr                    | 43 (43.9%)          | 25 (41.6%)           | 18 (47.4%)         | 0.612   |
| Greater than 12 hr                 | 55 (56.1%)          | 35 (58.4%)           | 20 (52.6%)         |         |
| Co-morbidities and risk factors    |                     |                     |                     |         |
| Smoking                            | 69 (70.4%)          | 39 (65%)             | 30 (78.9%)         | 0.105   |
| HTN                                | 49 (50%)            | 29 (48.3%)           | 20 (52.6%)         | 0.492   |
| DM                                 | 18 (18.3%)          | 13 (21.7%)           | 5 (13.2%)          | 0.405   |
| Family history                     | 21 (21.4%)          | 13 (21.7%)           | 8 (21.1%)          | 0.983   |
| Previous MI history                | 12 (12.2%)          | 7 (11.6%)            | 5 (13.2%)          | 0.743   |
| MI type                            |                     |                     |                     |         |
| STEMI                              | 86 (87.8%)          | 54 (90%)             | 32 (84.2%)         | 0.123   |
| NSTEMI                             | 12 (12.2%)          | 6 (10%)              | 6 (15.8%)          |         |
| Number of diseased vessels         |                     |                     |                     |         |
| Multi-vessel                       | 30 (30.6%)          | 18 (30%)             | 12 (31.6%)         | 0.902   |
| Single vessel                      | 68 (69.4%)          | 42 (70%)             | 26 (68.4%)         |         |
| Physical findings                  |                     |                     |                     |         |
| HR, beat/min                       | 78.35±15.33         | 77.06±16.68          | 79.23±24.12        | 0.604   |
| SBP, mmHg                          | 125.88±23.26        | 122.15±23.44         | 132.42±21.92       | 0.047*  |
| DBP, mmHg                          | 80.36±16.35         | 77.65±15.77          | 84.36±16.81        | 0.066   |
| Laboratory findings                |                     |                     |                     |         |
| TnI, ng/ml                         | 3070.4 (311.57, 18527.20) | 6705.75 (549.70, 39951.52) | 1328.50 (132.35, 10885.20) | 0.035* |
| Scr, umol/l                        | 74.10±22.06         | 74.75±20.87          | 73.71±24.12        | 0.838   |
| Medications at discharge           |                     |                     |                     |         |
| Antiplatelet, %                    | 98 (100%)           | 60 (100%)            | 38 (100%)          | 1       |
| ACEI/ARB, %                        | 96 (97.9%)          | 59 (98.3%)           | 37 (97.4%)         | 0.765   |
| Beta-blockers, %                   | 81 (82.6%)          | 48 (80%)             | 33 (86.8%)         | 0.331   |
| Statin, %                          | 97 (98.9%)          | 60 (100%)            | 37 (97.4%)         | 0.398   |

* p calculated using independent t test; † p value calculated using Mann–Whitney U test; p <0.05 was considered statistically significant.

BMI, body mass index; GRACE score, Global Registry of Acute Coronary Events score; HTN, hypertension; DM, diabetes mellitus; MI, myocardial infarction; STEMI, ST-segment elevation myocardial infarction; NSTEMI, non ST-segment elevation myocardial infarction; HR, heart rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; TnI, troponin I; Scr, serum creatinine; ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers. Data are mean±standard deviation, median (first quartile, third quartile), or number (%).
echocardiographic parameters and NT-proBNP were assessed by the Spearman’s correlation coefficient. Receiver operating characteristic (ROC) curves and area under the curves (AUC) were analyzed for prediction of LV dysfunction. Statistical significance was defined as a p value <0.05.

Results

Of all 98 participants, 80 (81.6%) were males, and the mean age was 56.0±9.3 yrs. Baseline echocardiography showed that 82 (83.7%) participants had mid-range or preserved LVEF≥40%, and only 16 (16.3%) had LVEF <40%. While the majority of participants (60, 61.2%) had abnormal GLS (GLS<16%), the remainder (38, 38.8%) had normal or borderline GLS (GLS ≥16%). The basic characteristics of the participants with normal GLS group (86.8% male, mean age 55.0±10.05 years) and abnormal GLS group (78.3% male, mean age 56.6±8.8 yrs) are summarized in Table 1.

As described in Table 1, there were no significant differences in age, gender, the time from onset to hospital admission, presence of co-morbid risk factors, type of MI, kidney function, heart rate, prescribed medication and number of vessels involved in patients of the two groups. In contrast, significant differences in troponin I concentration, Global Registry of Acute Coronary Events (GRACE) Score, and systolic blood pressure were observed. Patients with abnormal GLS had a higher GRACE score, higher troponin I and lower systolic blood pressure.

Table 2 lists initial and 6-mo follow-up echocardiographic parameters, as well as values of NT-proBNP at different time points. There were significant differences in baseline echocardiographic LV systolic and diastolic function. Compared with the normal GLS group, patients with abnormal GLS had lower mean LVEF and decreased LV diastolic function, as indicated by higher average E/e’ and lower mean e’. However, at 6-mo follow-up, only LV systolic function variables remained significantly different between the two groups. In comparison to baseline, there was a significant improvement of GLS in the abnormal GLS group at 6-mo follow-up (p=0.04). At 6-mo follow-up, in the abnormal GLS group, GLS values were improved in 33 (56.9%) participants, were further decreased in 5 (8.9%) participants, and remained unchanged in 20 (34.5%) participants. In the normal GLS group, the majority of the participants’ GLS values remained in the normal range, but 11 (28.9%) participants had impaired GLS. During the 6-mo follow-up period, adverse events developed in 14 (14.3%) of 98 participants, and the incidence was significantly higher.

Table 2. Initial and follow-up echocardiographic findings, plasma NT-proBNP concentration and incidence of complications

| Characteristic | All patients (n=98) | Patients according to baseline GLS | p value |
|---------------|---------------------|-----------------------------------|---------|
|               | Less than 16% (n=60) | Greater than 16% (n=38)          |         |
| Baseline echocardiographic values |                     |                                   |         |
| GLS, %        | 14.58±3.14          | 12.64±2.24                        | 17.63±1.51 | <0.001* |
| LVEF, %       | 49.46±6.73          | 46.44±5.82                        | 54.03±5.32 | <0.001* |
| Average E/e’ | 12.26±4.00          | 13.50±4.50                        | 10.43±2.1 | <0.001* |
| Mean e’      | 7.19±1.88           | 6.70±1.34                         | 8.1±2.37  | 0.002*  |
| 6 mo echocardiographic values |                     |                                   |         |
| GLS, %        | 15.41±3.55          | 14.61±3.60                        | 17.05±2.89 | 0.013* |
| LVEF, %       | 51.02±8.42          | 49.08±8.64                        | 54.16±7.20 | 0.043* |
| Mean E/e’    | 11.15±3.50          | 11.64±3.79                        | 10.28±2.81 | 0.250   |
| Mean e’      | 7.6±2.37            | 6.69±2.12                         | 8.88±2.47 | 0.060   |
| NT-proBNP concentrations |                     |                                   |         |
| Baseline NT-proBNP, pg/ml | 971.50 (258, 3059.25) | 1736.50 (562, 3451.50) | 391 (100, 1863.50) | 0.002a |
| Discharge NT-proBNP, pg/ml | 1052 (359, 2313)   | 1450 (543, 2821.50) | 513.50 (230.50, 1220.75) | <0.001a |
| 6 mo NT-proBNP, pg/ml | 100 (100, 313) | 126.50 (100, 479.25) | 100 (100, 252) | 0.244   |

Incidences of complications during follow-up

| Overall | 14 (14.3%) | 12 (20%) | 2 (5.3%) | 0.042* |
| Hospitalization due to heart failure | 4 (4.1%) | 4 (6.67%) | – | 0.155 |
| Hospitalization due to unstable angina | 3 (3.1%) | 2 (3.33%) | 1 (2.63%) | 0.844 |
| Recurrent MI | 5 (5.1%) | 4 (6.67%) | 1 (2.63%) | 0.646 |
| Cardiovascular mortality | 2 (2%) | 2 (3.33%) | – | 0.520 |

*p calculated using independent t test; 'p calculated using Mann–Whitney U test; ‘p between initial and follow-up parameters calculated with either paired t test or Wilcoxon test. p <0.05 was considered statistically significant. GLS, global longitudinal strain; LVEF, left ventricular ejection fraction; E/e’, ratio between peak early mitral inflow velocity and early diastolic mitral annular velocity; mean e’, mean early diastolic mitral annular velocity; NT-proBNP, N-Terminal pro-B-type natriuretic peptide; MI, myocardial infarction.

Data are mean±standard deviation, median (first quartile, third quartile), or number (%).
in the abnormal GLS group. Compared with the normal GLS group, NT-proBNP was higher in the abnormal GLS group. Baseline and discharge NT-proBNP of the two groups differed significantly (p<0.05), but there was no difference in NT-proBNP at 6 mos. To determine whether the early NT-proBNP assessment correlated with the future changes in LV systolic function, we examined the relationship between baseline, discharge, and 6-mo NT-proBNP with baseline and 6-mo follow-up echocardiographic parameters. Table 3 shows that in the normal GLS group, NT-proBNP did not significantly correlate with echocardiographic variables at any time point. In the abnormal GLS group, baseline LV systolic function variables had a weak, negative correlation with baseline NT-proBNP and a moderate, negative correlation with discharge NT-proBNP. Discharge NT-proBNP also had a significant correlation with the 6-mo follow-up GLS, as did 6-mo NT-proBNP with follow-up LV systolic function variables.

To gain further insight into the association between NT-proBNP concentration and GLS at different time points for prediction of LV dysfunction, we generated receiver operating characteristic curves (Figure 1). For determining the effect of baseline GLS abnormality, ROC curve analysis AUC for baseline (Figure 1A) and discharge (Figure 1A) NT-proBNP concentrations were 0.73 (95% CI 0.60–0.85, p=0.001) and 0.77 (95% CI 0.66–0.87, p<0.001) respectively. Regarding the early prediction of follow-up GLS abnormality, the area under the ROC curve for discharge (Figure 1C) NT-proBNP concentration was significantly higher (0.70 (95% CI 0.55–0.84), p=0.016) compared to baseline NT-proBNP concentration (0.62 (95% CI 0.47–0.78), p=0.122). Whereas ROC curve analysis for 6-mo (Figure 1D) NT-proBNP concentration was 0.74 (95% CI: 0.57–0.90; p=0.012). The optimum cut-off value of discharge NT-proBNP was 688.5 pg/ml, with 72.4%...
sensitivity and 65.4% specificity to predict 6-mo GLS abnormality following AMI.

Discussion

In this study, we investigated association between GLS and plasma NT-proBNP concentrations for predicting LV dysfunction in post-AMI asymptomatic patients.

Baseline echocardiographic measurements of our study population showed that among patients with abnormal GLS, as many as 91.6% (n=54) presented with mid-range and preserved LVEF. Prior studies have reported that two thirds of patients diagnosed with AMI have preserved LVEF [17]. GLS is more prone to change early, so it has an advantage in evaluation of subclinical LV dysfunction in a variety of cardiac disorders, including MI [18, 19]. At 6-mo follow-up, there was a significant improvement in LV function as assessed by GLS in patients with initial impairment. However, compared with the normal GLS group, this group of participants had greater incidence of adverse events after discharge. As described in previous studies, GLS is a more sensitive predictor of myocardial functional recovery [20], LV remodeling [21], and major adverse events [22] in post-AMI patients. Additionally, long and short term follow-up studies have noted that following PCI, persistently abnormal or decreased GLS compared to the initial GLS presentation is associated with a higher risk of complications [23, 24].

Our study showed that plasma NT-proBNP concentrations were significantly higher in patients with abnormal GLS in the early stages of AMI. Both experimental animal and clinical investigations observed immediate and rapid secretion of NP during myocardial hypoxia and ischemia. As NT-proBNP is released immediately after myocardial infarction, peak concentrations are achieved within 24 to 36 hrs after onset and will decrease significantly following successful reperfusion [12, 25]. Our results are consistent with this finding. In this study we investigated relationships between NT-proBNP concentrations and LV systolic function at different time points. Results showed that assessment of NT-proBNP at acute and subacute phases of AMI had a significantly stronger relationship to GLS compared to LVEF. Positive correlations were found between baseline and follow-up GLS with discharge NT-proBNP concentration. This means that discharge NT-proBNP concentration could be a reliable predictor of baseline and follow-up LV dysfunction.

Very few studies have demonstrated a relationship between GLS and NP in AMI. Ersbøll et al. described that in post-MI patients, impaired GLS had a strong correlation to plasma NT-proBNP concentration as well as to the risk of HF during hospitalization [26]. Thus, in post-MI asymptomatic patients, LV global longitudinal strain and plasma NT-proBNP concentration could reflect an intrinsic abnormality of LV function. We found that baseline and discharge NT-proBNP concentrations could equally predict baseline GLS abnormality. Whereas for prediction of LV dysfunction at 6 mos, only discharge NT-proBNP concentration had predictive value. Prognostic significance of plasma NT-proBNP at different time points in AMI have been described previously, but still there is concern about optimal timing of NT-proBNP measurement for better prediction of clinical outcome. Heeschen C et al. reported that in acute coronary syndrome, a higher NT-proBNP concentrations after 72 hrs of onset was linked to short term adverse prognosis [13]. Also Eurlings LW et al. [27] reported that NT-proBNP concentrations at discharge or soon after discharge were associated with the outcome. Our findings are similar to these findings. Instead of admission NT-proBNP concentration, NT-proBNP at discharge was a better predictor of 6-mo LV dysfunction. This indicates that early NT-proBNP concentration is more related to myocardial necrosis-induced release of natriuretic peptide, but in the subacute phase, release of the NT-proBNP corresponds to infarct expansion and evolution of LV systolic dysfunction following AMI.

In summary, we observed that combination of initial LV GLS and NT-proBNP concentration at pre-discharge improves personalized stratification and identification of patients needing intensive monitoring and early optimization of treatment to prevent future cardiovascular complications.

Limitations of this study include the small sample size. Thus, further studies are required for clarification. Also, pre-discharge NT-proBNP measurements were not conducted at one standardized time point. Blood sampling was performed 3–5 days after admission, so we cannot fully exclude a possible influence of the time differences in blood sampling. Furthermore, 12% of the participants had previous MI history, which could have impacted the evolution of LV systolic function.

Conclusion

The main finding of this study is that impaired LV GLS is associated with elevated plasma concentrations of NT-proBNP in post AMI patients. Pre-discharge NT-proBNP concentration combined with impaired initial GLS could predict worsening LV systolic function over time in asymptomatic post-AMI patients.

Funding

This study was financially supported by a research grant from the Science Technology Foundation, Ministry of Education, Culture, Sciences and Sports, Mongolia.

No conflict of interest is reported.

The article was received on 18/05/2021
В дополнительной защите после эпизода декомпенсации СН

Пациенты особенно уязвимы в ранний период после стабилизации состояния.

- Ежегодно у ~30% пациентов с симптоматической хронической СН развиваются эпизоды декомпенсации СН.
- В России повторные госпитализации после эпизода острой декомпенсации СН регистрируются у 31% пациентов в течение 1 месяца, а у 63,4% — на протяжении первого года.
- Смертность пациентов с СНФВ в течение 3 лет после выписки из стационара составляет от 20% до 48%.

Патофизиологические механизмы развития СН и возможные точки приложения лекарственных препаратов, улучшающих прогноз:

- Нестабильная фракция выброса (НФВ)
- Снижение биодоступности NO и активности rГЦ
- Активация и синаптическая нервная система
- Повышенная активация гипертрофии ЛЖ и ремоделирования ЛЖ
- Вазоконстрикция
- Гипертрофия и ремоделирование ЛЖ

Угнетение сигнального пути NO-rГЦ-циГМФ имеет важное значение в прогрессировании заболевания.

NO - оксид азота, ЛЖ - левый желудочек, PAAC - внутрепетитикулярная альдостероновая система; rГЦ - расторможенная гуаннозинмонофосфат; СН - сердечная недостаточность; СНФВ - сердечная недостаточность со сниженной фракцией выброса; цГМФ - циклический гуаннозинмонофосфат

* На основании анализа серии пациентов с хронической СН после эпизода острой декомпенсации СН: в первые 6 месяцев наблюдалась максимальная относительная различия показателей общего и сердечно-сосудистой смертности между пациентами (n=510), наблюдающимися в специализированном центре лечения СН, и пациентами (n=432), наблюдающимися в амбулаторно-поликлинических учреждениях по месту жительства.

Литература: 1. Greene SI, Fozzard GC, Butler J. Circ Heart Fail. 2020;13(9):e007132. 2. Векторсона И.Г., Половин Д.С., Иванов И.В. Кардиология. 2020:60(4):91-100. 3. Builer I, Yang M, Mazi MA, et al. J Am Coll Cardiol. 2019;73(9):935-944. 4. Арутюнов А.Г., Лягушко Д.О., Арутюнов Г.Л. и др. Кардиология. 2015;55(5):12-21. 5. Сапунова М.Ю., Лисюк В.А., Юрченко А.В. и др. Кардиология. 2018;58(105):9-19. 6. Munt DL, et al. Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine. 11th ed. Elsevier/Saunders; 2020. 7. Himid M, Aimo A, Castiglione V, et al. J Am Coll Cardiol. 2020 Oct 13;76(15):1795-1807. 8. Bremskamp S, Roessig L, Sandner P, Lewis KJ. H上演 Hyp Press 2017;245:225-247.
1. World Health Organisation. Health Indicators 2018. Av. at: http://www.hdc.gov.mn/media/uploads/2019-11/2018eng.pdf.
2. Tsogzolbaatar EO, Kotani K, Swanson E. Ischemic heart disease among the general Mongolian population: a review of epidemiological studies. International Health. 2015;8(1):13–7. DOI: 10.1093/inthealth/ihv064
3. Brooks GC, Lee BK, Rao R, Lin F, Morin DP, Zweibel SL et al. Predicting Persistent Left Ventricular Dysfunction Following Myocardial Infarction. Journal of the American College of Cardiology. 2016;67(10):1186–96. DOI: 10.1016/j.jacc.2015.12.042
4. Sara JD, T oya T, Taher R, Lerman A, Gersh B, Anavekar NS. Asymptomatic Left Ventricle Systolic Dysfunction. European Cardiology Review. 2020;15:e13. DOI: 10.15420/erc.2019.14
5. Mielniczuk LM, Lamas GA, Flaker GC, Mitchell G, Smith SC, Gersh BJ et al. Left Ventricle End-Diastolic Pressure and Risk of Subsequent Heart Failure in Patients Following an Acute Myocardial Infarction: Congestive Heart Failure pertaining to Left Ventricular Systolic Function and Congestive Heart Failure After Acute Myocardial Infarction. The American Journal of Cardiology. 1998;81(11):1292–7. DOI: 10.1016/S0002-9199(98)00158-1
6. Kober L, Torp-Pedersen C, Jørgensen S, Eliasen P, Camm AJ. Changes in Absolute and Relative Importance in the Prognostic Value of Left Ventricular Systolic Dysfunction and Congestive Heart Failure After Acute Myocardial Infarction. European Journal of Heart Failure. 2007;13(4):209–14. DOI: 10.1111/j.1527-5299.2007.06624.x
7. Stanton T, Marwick TH. Assessment of Subendocardial Structure and Function. JACC: Cardiovascular Imaging. 2010;3(8):867–75. DOI: 10.1016/j.jcmg.2010.05.011
8. Potter E, Marwick TH. Assessment of Left Ventricular Function by Echocardiography, JACC: Cardiovascular Imaging. 2018;11(2):260–74. DOI: 10.1016/j.jcmg.2017.11.017
9. Tops LF, Delgado V, Marsan NA, Bax JJ. Myocardial strain to detect subtle left ventricular systolic dysfunction. European Journal of Heart Failure. 2017;19(3):307–13. DOI: 10.1002/ejhf.694
10. Russo C, Jin Z, Elkind MSV, Rundek T, Homma S, Sacco RL et al. Prevalence and prognostic value of subclinical left ventricular systolic dysfunction by global longitudinal strain in a community-based cohort. European Journal of Heart Failure. 2014;16(12):1301–9. DOI: 10.1002/ejhf.154
11. Chung H. Myocardial Longitudinal Strain in Prediction of Heart Failure after Acute Myocardial Infarction. Korean Circulation Journal. 2019;49(10):973–4. DOI: 10.4070/kcj.2019.0132
12. Goetzte JP, Gore A, Møller CH, Steinbrüchel DA, Rehfeld JF, Nielsen LB. Acute myocardial hypoxia increases BNP gene expression. The FASEB Journal. 2004;18(15):1928–30. DOI: 10.1096/fj.03-1336fje
13. Heeschen C, Hamm CW, Mitrovic V, Lantelme N-H, White HD. Prevalence and prognostic value of subclinical left ventricular systolic dysfunction associated with increased neurohormonal activation after acute myocardial infarction: a two-dimensional speckle tracking study. European Journal of Heart Failure. 2012;14(10):1121–9. DOI: 10.1093/eurheartj/ehs107
14. Ersboll M, Valeur N, Mogensen UM, Andersen M, Greibe R, Bolerslev CJWT, Boerslev JH et al. Prognostic Value of Serial Global Longitudinal Strain Measured by Two-Dimensional Speckle Tracking Echocardiography in Patients With ST-Segment Elevation Myocardial Infarction. The American Journal of Cardiology. 2011;108(3):340–7. DOI: 10.1016/j.amjcard.2011.03.052
15. Buchner S, Debl K, Barlage S, Griese D, Fredersdorf S, Jeron A et al. Dynamic changes in N-terminal pro-brain natriuretic peptide in acute coronary syndromes treated with percutaneous coronary intervention: a marker of ischemic burden, repercussion and outcome. Clinical Chemistry and Laboratory Medicine. 2010;48(6):875–81. DOI: 10.1515/CCLM.2010.164
16. Thysen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA et al. Fourth universal definition of myocardial infarction (2018). European Heart Journal. 2019;40(3):237–69. DOI: 10.1093/eurheartj/ehy462
17. Gagnis HK, Januzzi JL. The past, the present, and the future of natriuretic peptides in the diagnosis of heart failure. European Heart Journal Supplements. 2018;20(Suppl G):G11–20. DOI: 10.1093/eurheartj/suy024
18. Yang H, Wright L, Negishi T, Negishi K, Liu J, Marwick TH. Research to Practice: Assessment of Left Ventricular Global Longitudinal Strain for Surveillance of Cancer Chemotherapeutic-Related Cardiac Dysfunction. JACC: Cardiovascular Imaging. 2018;11(8):1196–201. DOI: 10.1016/j.jcmg.2018.07.005
19. Choo EH, Chang K, Ayn Y, Jeon DS, Lee JM, Kim DB et al. Benefit of β-blocker treatment for patients with acute myocardial infarction and preserved systolic function after percutaneous coronary intervention. Heart. 2014;100(6):492–9. DOI: 10.1136/heartjnl-2013-305137
20. Smiseth OA, Torp H, Opdahl A, Haugaa KH, Urheim S. Myocardial strain imaging: how useful is it in clinical decision making? European Heart Journal. 2016;37(15):1196–207. DOI: 10.1093/eurheartj/ehv529
21. Bochenek T, Wita K, Tabor Z, Grabka M, Krzyczk L, Wrobel W et al. Value of Speckle-Tracking Echocardiography for Prediction of Left Ventricular Remodeling in Patients With ST-Elevation Myocardial Infarction Treated by Primary Percutaneous Intervention. Journal of the American Society of Echocardiography. 2011;24(12):1342–8. DOI: 10.1016/j.echo.2011.09.003
22. Antoni ML, Mollena SA, Delgado V, Atary JZ, Bolerslev CJWT, Boerslev JH et al. Prognostic importance of strain and strain rate after acute myocardial infarction. European Heart Journal. 2010;31(13):1640–7. DOI: 10.1093/eurheartj/ehq105
23. Ghanem IGA. Predictors of myocardial functional recovery following successful reperfusion of acute ST elevation myocardial infarction. Echocardiography. 2018;35(10):1571–8. DOI: 10.1111/echo.14106
24. D’Andrea A, Cochia R, Caso P, Riegler L, Scarafile R, Salerno G et al. Global longitudinal speckle-tracking strain is predictive of left ventricular remodeling after coronary angioplasty in patients with recent non-st elevation myocardial infarction. International Journal of Cardiology. 2011;153(2):185–91. DOI: 10.1016/j.ijcard.2010.08.025
25. Buhrer N, Debl K, Barlage S, Griese D, Fredersdorf S, J eron A et al. Dynamic changes in N-terminal pro-brain natriuretic peptide in acute coronary syndromes treated with percutaneous coronary intervention: a marker of ischemic burden, repercussion and outcome. Clinical Chemistry and Laboratory Medicine. 2010;48(6):875–81. DOI: 10.1515/CCLM.2010.164
26. Ersboll M, Valeur N, Mogensen UM, Andersen M, Greibe R, M eller JE et al. Global left ventricular longitudinal strain is closely associated with increased neurohormonal activation after acute myocardial infarction in patients with both reduced and preserved ejection fraction: a two-dimensional speckle tracking study. European Journal of Heart Failure. 2012;14(10):1121–9. DOI: 10.1093/eurheartj/ehs107
27. Eurlings LW, Sanders-van Wijk S, van Kraaij DJW, van Kammenade R, Meeder JG, Kamp O et al. Risk Stratification with the Use of Serial N-Terminal Pro-B-Type Natriuretic Peptide Measurements During Admission and Early After Discharge in Heart Failure Patients: Post Hoc Analysis of the PRIMA Study. Journal of Cardiac Failure. 2014;20(12):881–90. DOI: 10.1016/j.cardfail.2014.08.014